Tech Company Financing Transactions
Endogenex Funding Round
Hatteras Venture Partners, Intuitive Venture Partners and Longitude Capital Management participated in a $88 million Series C funding round for Endogenex. This VC investment round was announced by the company on 6/25/2024.
Transaction Overview
Company Name
Announced On
6/25/2024
Transaction Type
Venture Equity
Amount
$88,000,000
Round
Series C
Investors
Proceeds Purpose
The company intends to use the funds to complete the pivotal ReCET Clinical Study, which has been granted an Investigational Device Exemption (IDE) by the U.S. Food and Drug Administration (FDA).
Company Information
Company Status
Private & Independent
Industry
Medical Devices & Instruments
Mailing Address
13755 1st Ave North 100
Plymouth, MN 55441
USA
Plymouth, MN 55441
USA
Phone
Website
Email Address
Overview
Endogenex, in partnership with Mayo Clinic, aims to revolutionize treatment options for individuals with type 2 diabetes (T2D). Endogenex's innovations focus on resetting the body's metabolic signaling system by harnessing its natural regenerative capabilities to improve metabolic function.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Stacey Pugh
Chief Marketing Officer
Chris Sorli
VP - Marketing
Brent Collins
VP - R & D
Matt Cambronne
VP - Regulatory Affairs
Lian Cunningham
VP - Regulatory Affairs
Melanie Hess
Browse more venture capital transactions:
Prev: 6/25/2024: Topicflow venture capital transaction
Next: 6/25/2024: Micruity venture capital transaction
Share this article
News on VC Transactions
We report on all VC transactions involving tech companies. VC investment data records reported here are sourced from company press releases and news coverage. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs